Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.

Phase 1 Recruiting 24 enrolled RNATICS GmbH LungenClinic Grosshansdorf · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of RCS-21 in healthy volunteers. Participants will be asked to inhale a single dose of RCS-21 and their health status will be constantly monitored.

Timeline

Start: 2025-02-18
Primary completion: 2026-06
Completion: 2026-08

Publications

Background Beck C, Ramanujam D, Vaccarello P, Widenmeyer F, Feuerherd M, Cheng CC, Bomhard A, Abikeeva T, Schadler J, Sperhake JP, Graw M, Safi S, Hoffmann H, Staab-Weijnitz CA, Rad R, Protzer U, Frischmuth T, Engelhardt S. Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage. Nat Commun. 2023 Jul 28;14(1):4564. doi: 10.1038/s41467-023-40185-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RCS-21	Unknown	0.5 mg	Inhaled
Subject	RCS-21	Unknown	1.5 mg	Inhaled
Subject	RCS-21	Unknown	4.5 mg	Inhaled

Indications

No indication recorded.